Clinuvel Pharmaceuticals 관리
관리 기준 확인 2/4
Clinuvel Pharmaceuticals CEO는 Philippe Wolgen, Nov2005 에 임명되었습니다 의 임기는 19.08 년입니다. 총 연간 보상은 A$ 3.74M, 47.2% 로 구성됩니다. 47.2% 급여 및 52.8% 보너스(회사 주식 및 옵션 포함). 는 A$ 45.08M 가치에 해당하는 회사 주식의 6.86% 직접 소유합니다. 45.08M. 경영진과 이사회의 평균 재임 기간은 각각 0.9 년과 5 년입니다.
주요 정보
Philippe Wolgen
최고 경영자
AU$3.7m
총 보상
| CEO 급여 비율 | 47.2% |
| CEO 임기 | 19yrs |
| CEO 소유권 | 6.9% |
| 경영진 평균 재임 기간 | less than a year |
| 이사회 평균 재임 기간 | 5yrs |
최근 관리 업데이트
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | AU$4m | AU$2m | AU$36m |
| Mar 31 2024 | n/a | n/a | AU$33m |
| Dec 31 2023 | n/a | n/a | AU$30m |
| Sep 30 2023 | n/a | n/a | AU$30m |
| Jun 30 2023 | AU$6m | AU$2m | AU$31m |
| Mar 31 2023 | n/a | n/a | AU$29m |
| Dec 31 2022 | n/a | n/a | AU$26m |
| Sep 30 2022 | n/a | n/a | AU$24m |
| Jun 30 2022 | AU$7m | AU$1m | AU$21m |
| Mar 31 2022 | n/a | n/a | AU$22m |
| Dec 31 2021 | n/a | n/a | AU$24m |
| Sep 30 2021 | n/a | n/a | AU$24m |
| Jun 30 2021 | AU$5m | AU$2m | AU$25m |
| Mar 31 2021 | n/a | n/a | AU$23m |
| Dec 31 2020 | n/a | n/a | AU$21m |
| Sep 30 2020 | n/a | n/a | AU$18m |
| Jun 30 2020 | AU$3m | AU$2m | AU$15m |
| Mar 31 2020 | n/a | n/a | AU$15m |
| Dec 31 2019 | n/a | n/a | AU$15m |
| Sep 30 2019 | n/a | n/a | AU$16m |
| Jun 30 2019 | AU$1m | AU$894k | AU$18m |
| Mar 31 2019 | n/a | n/a | AU$17m |
| Dec 31 2018 | n/a | n/a | AU$16m |
| Sep 30 2018 | n/a | n/a | AU$15m |
| Jun 30 2018 | AU$2m | AU$818k | AU$13m |
보상 대 시장: Philippe 의 총 보상 ($USD 2.44M )은 Australian 시장( $USD 910.58K ).
보상과 수익: Philippe 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Philippe Wolgen (61 yo)
19yrs
테뉴어
AU$3,742,412
보상
Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, MD & Director | 19yrs | AU$3.74m | 6.86% A$ 45.9m | |
| Chief Scientific Officer | 12.2yrs | AU$782.61k | 0.38% A$ 2.5m | |
| Chief Financial Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Operations Officer | no data | 데이터 없음 | 데이터 없음 | |
| Head of Australian Operations & Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Regulatory Affairs | less than a year | 데이터 없음 | 데이터 없음 | |
| Head of Quality Assurance & Drug Safety | less than a year | 데이터 없음 | 데이터 없음 | |
| Company Secretary | less than a year | 데이터 없음 | 데이터 없음 |
0.9yrs
평균 재임 기간
경험이 풍부한 관리: CUV 의 관리팀은 경험 (평균 재직 기간 0.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, MD & Director | 19.1yrs | AU$3.74m | 6.86% A$ 45.9m | |
| Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Non-Executive Director | 5.2yrs | AU$80.00k | 0.00084% A$ 5.6k | |
| Non-Executive Chairman | 5yrs | AU$91.67k | 0.0063% A$ 42.2k | |
| Non-Executive Director | 6.8yrs | AU$75.00k | 0.028% A$ 185.4k | |
| Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 |
5.0yrs
평균 재임 기간
경험이 풍부한 이사회: CUV 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.